Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Mean (± SD) serum concentration of IPH5201 across dose cohorts and treatment. Data are shown based on the PK analysis set, defined as patients who received ≥1 dose of IPH5201 or durvalumab (durva) and provided ≥1 quantifiable posttreatment sample. Vertical lines represent the geometric ± SD. Geometric mean SD was calculated as the exponential [mean (log (PK concentration)) ± SD (log (PK concentration))]. PK, pharmacokinetic; SD, standard deviation.
Authors: John Powderly, Martina Imbimbo, Antoine Italiano, Patricia Martin-Romano, Meredith McKean, Teresa Macarulla, Eduardo Castañón Alvarez, Benedito A. Carneiro, Raymond Mager, Vicky Barnhart, Steven Eck, Elina Murtomaki, Arsène-Bienvenu Loembé, Yun He, Zachary A. Cooper, Eric Tu, Chunling Fan, Agnes Boyer Chamard, Carine Paturel, Paula G. Fraenkel, Antoine Hollebecque
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414394279
Cites:
Cited by:
Related to: